Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02837705 · ClinicalTrials.gov registry record
Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers
A clinical trial, sponsored by University of Zurich.
- Completed
- Registry status
- 213
- Enrollment target
NCT02837705: Completed study, sponsored by University of Zurich.
NCT02837705 is a clinical trial that has completed, run by University of Zurich. The registered enrollment target is 213 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02837705 has completed, sponsored by University of Zurich.
- COMPLETED
- Registry status
- 213 participants
- Enrollment target
Study Summary
The human Prion diseases can be classified into sporadic, acquired and inherited forms. Inherited forms usually manifest in higher age so there have to be factors preventing Prion propagation in young mutation carriers. Antibodies against the flexible tail of Prions have been shown to be protective in mice. The investigators intend to screen mutation carriers and controls for the presence of Prion autoantibodies.
Interventions
- OTHER blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2019-03-01 |
What the finished NCT02837705 record still lists
NCT02837705 is an observational study that tracks outcomes without assigning an intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which blood draw is the first listed.
NCT02837705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02837705 about?
NCT02837705 is a clinical study titled "Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers". The human Prion diseases can be classified into sporadic, acquired and inherited forms. Inherited forms usually manifest in higher age so there have to be factors preventing Prion propagation in young mutation carriers. Antibodies against the flexible tail of Prions have been shown to be protective ...
What is the current status of trial NCT02837705?
This trial is currently completed. The enrollment target is 213 participants. The study started on 2015-09-01. Estimated completion is 2019-03-01.
What interventions are being tested in trial NCT02837705?
The interventions under investigation include: blood draw (OTHER).
Who is sponsoring clinical trial NCT02837705?
This trial is sponsored by University of Zurich, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI